Gibson Dunn Advises Mentari Therapeutics on Merger With InMed Pharmaceuticals and Concurrent $290 Million Private Placement
Gina Spinosa
Gibson Dunn is advising Mentari Therapeutics, Inc. on its merger with InMed Pharmaceuticals, Inc. and concurrent $290 million private placement. The post Gibson Dunn Advises Mentari Therapeutics on Merger With InMed Pharmaceuticals and Concurrent $290 Million Private Placement appeared first on Gibson Dunn .